

NDC Reservation

David Mazyck

Consumer Safety Officer

Division of Labeling, Registration, and Unapproved Drugs

Office of Unapproved Drugs & Labeling Compliance

CDER | US FDA

eDRLS Using CDER Direct 2024 - September 12, 2024

Objectives



- Describe the required elements for the NDC Reservation file.
- Provide details on the timeframe for submitting the file.
- Explain the importance of the use of the NDC Reservation.

Benefits



- Preparation for a product launch
- The proposed NDC is reserved for 2 years once accepted
- Prevention of duplicated and formatting issues before drug listing
- CMOs can reserve an NDC using a PLD's labeler code

Who Should Reserve?



- Preparation for a product launch- Printing labels
- CMOs responsible for the PLD's drug listing
- Reservations should be used if the company is uncertain of the marketing status, unsure of the product's final approved formulation, and the final physical characteristics (imprint information, color shape etc.)

When to Reserve



- If the NDC appears on the label:
- Prior to final labeling approval and printing
- The reservation is not required prior to the actual listing submission
- Do not reverse an NDC if you do not intend to start the commercial distribution within 2 years.



- The labeler code included in the reservation SPL, should be a labeler code that is electronically assigned by and submitted to FDA.
- Required data elements for NDC Reservation:
 - Labeler Name, Labeler DUNS, NDC Product Code, Non-Proprietary Name, Dosage Form, Marketing Status, Reserved Until Date, and 1 Active Ingredient.





- NDCs under <u>the same labeler code</u> can be reserved on the same NDC Reservation SPL
- Once accepted, the proposed NDC is reserved
- NDC is reserved at the product level:
 - Labeler Code and Product Code
 - No packaging information needed
- No additional data is "required" for NDC Reservation



- Marketing Status for all reserved NDC is "New" or "Reserved"
- To convert an NDC Reservation SPL to a Listing SPL, the Marketing Status must be switched from "Reserved" to "Active"
- A Reserved NDC that is no longer needed can be canceled
- To cancel an NDC Reservation, change the Marketing Status from "Reserved" to "Cancel"



- Cancelling an NDC Reservation is effective on day of submission
- A reserved NDC, will not be available for reservation or listing of other products
- An NDC Reservation cannot be submitted for an NDC which has already been used
- A previously reserved NDC becomes available once its reservation is canceled

CDER Direct: NDC Reservation





All Submissions NDC Reservation

ESTABLISHMENT REGISTRATION & DRUG

Establishment Registration

NDC Labeler Code Request

Drug Listing and Certification

NDC Reservation

NDC RESERVATION

For assistance with validation errors in CDER Direct, contact CDERdirect@fda.hhs.gov. For general questions regarding electronic establishment registration and drug listing, contact eDRLS@fda.hhs.gov.

- NDC Reservation IS NOT a drug listing submission. It reserves an NDC for a future drug listing with the FDA, confirming availability of the NDC during product development.
- . NDC reservation is not required prior to a drug listing submission
- . NDC Reservation SPL Document Type should only be selected to reserve an NDC for up to 2 years
- . DO NOT reserve an NDC if you do not intend to start commercial distribution within 2 years.
- . Once commercial distribution begins, the NDC Reservation SPL must be updated to a Drug Listing SPL with all required data elements to list the drug product with FDA.

Challenge Question #1



Which of the following data elements can be excluded from the NDC reservation file?

- A. Labeler Name
- **B.** Labeler DUNS
- C. Package Code
- D. Active ingredient

Challenge Question #2



 NDC reservation is required to facilitate the listing submission. T/ F

Question #3



 Reservation data is published on the NDC directory. T/F

Summary



- NDC Reservation SPL Document Type should only be selected to reserve an NDC for up to 2 years.
- The NDC reservation is not a complete drug listing submission.



Questions?

David Mazyck

Consumer Safety Officer

Division of Labeling, Registration, and Unapproved Drugs

Office of Unapproved Drugs & Labeling Compliance

CDER | US FDA